Wedbush Upgrades Karyopharm Therapeutics (KPTI) to Outperform
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.06 -2.75%
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 1
Join SI Premium – FREE
Wedbush analyst David Nierengarten upgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Outperform with a price target of $19.00.
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $11.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
- Stifel Upgrades LeMaitre Vascular (LMAT) to Buy
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
